Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ4 | P56696 | 1/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33525705 | 0.84 | AAK1 (0.41) | KCNQ4KCNQ5AAK1CTSSCTSK | |
| SCHEMBL33526231 | 0.83 | CTSS (0.36) | KCNQ4KCNQ5AAK1CTSSCTSK | |
| SCHEMBL33526532 | 0.83 | KEAP1 (0.38) | KCNQ4KCNQ5AAK1CTSSCTSK | |
| SCHEMBL29726461 | 0.81 | GRM2 (0.44) | AAK1CTSSCTSKGRM2HDAC1 | |
| SCHEMBL19491486 | 0.78 | NR1H2 (0.40) | AAK1 | |
| SCHEMBL33526561 | 0.77 | DDB1 (0.38) | KCNQ4KCNQ5AAK1SSTR4 | |
| SCHEMBL16410342 | 0.76 | MTNR1A (0.47) | HDAC1SLC6A2SLC6A4SLC6A3HDAC2 | |
| SCHEMBL6676311 | 0.76 | ALDH1A1 (0.42) | — | |
| SCHEMBL33526461 | 0.76 | TSHR (0.41) | — | |
| SCHEMBL27641590 | 0.75 | KEAP1 (0.36) | HDAC1SLC6A2SLC6A4SLC6A3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | KCNQ4 2094/4885KCNQ5 2349/4885AAK1 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.